Translating Molecular Advances in Fragile X Syndrome Into Therapy: A Review
J Clin Psychiatry 2014;75(4):e294-e307
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Fragile X syndrome is an inherited disease with cognitive, behavioral, and neurologic manifestations, resulting from a single genetic mutation. A variety of treatments that target individual symptoms of fragile X syndrome are currently utilized with limited efficacy. Research in animal models has resulted in the development of potential novel pharmacologic treatments that target the underlying molecular defect in fragile X syndrome, rather than the resultant symptoms. This review describes recent advances in our understanding of the molecular basis of fragile X syndrome and summarizes the ongoing clinical research programs.
J Clin Psychiatry 2014;75(4):e294–e307
© Copyright 2014 Physicians Postgraduate Press, Inc.
Submitted: August 5, 2013; accepted January 16, 2014 (doi:10.4088/JCP.13r08714).
Corresponding author: Baltazar Gomez-Mancilla, MD, PhD, Department of Neuroscience, Translational Medicine, Novartis Institutes of Biomedical Research, WSJ.210.25.5, CH-4056 Basel, Switzerland (email@example.com).